Health · 1 views

Opna Bio Announces Orphan Drug Designation Granted to OPN - 2853 ( Zavabresib ) for the Treatment of Mye

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and developme…

Source pharmiweb.com AI Summary Updated January 21, 2026

Story intelligence Beta

Freshness Stale Updated January 21, 2026

Confidence Limited Single-outlet story

Coverage Single outlet

Views 1 Community interest

Read time 1 min ~27 words

AI Summary

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, today announced that OPN-2853, a bromodomain and…

Read full article on Pharmiweb

AI summaries can be wrong sometimes—always verify important details using the source article.